Autoantibody Profiling for Serological Detection of Head and Neck Cancer

用于头颈癌血清学检测的自身抗体分析

• 批准号: 7671946
• 负责人: Nada H Khattar
• 金额: $ 21.78万
• 依托单位: 20/20 GENESYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7671946
• 关键词: Advanced Development; Affect; Agreement; Alcohols; Applications Grants; Autoantibodies; Bacteriophages; Binding; Bioinformatics; Biological Assay; Biological Markers; Blinded; Blood; Blood Tests; Blood specimen; Caring; Classification; Clinical; Collaborations; Consult; Curative Surgery; Data; Detection; Development; Diagnosis; Diagnostic; Diagnostic Neoplasm Staging; Disease; Doctor of Philosophy; Early Diagnosis; Failure; Feasibility Studies; Floods; Funding; Grant; Head; Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Immune; Immunoassay; Kentucky; Legal patent; Lesion; Licensing; Lung Neoplasms; Malignant neoplasm of lung; Mediation; Medical; Modality; Non-Small-Cell Lung Carcinoma; Patients; Peptides; Persons; Phage Display; Phase; Physicians; Plasma; Population; Premalignant; Process; Protein Microchips; Proteomics; Publications; Publishing; Rights; Risk; Sampling; Screening procedure; Serologic tests; Serological; Serum; Small Business Innovation Research Grant; Smoker; Specificity; Staging; Symptoms; Techniques; Technology; Testing; Therapeutic; Tobacco; Training; Translations; Universities; Upper arm; Validation; Work; X-Ray Computed Tomography; base; cancer diagnosis; cost; high risk; innovative technologies; interest; mortality; novel; outcome forecast; patient population; public health relevance; tool; tumor; validation studies

DESCRIPTION (provided by applicant): SBIR grant support is being sought by 20/20 GeneSystems, Inc. (20/20), a small biotech company, to help us advance what we believe will become the first blood test to be routinely employed to aid in the early detection of head and neck cancer. Despite recent advances in both diagnostic and therapeutic modalities, long-term prognosis for patients affected by advanced stage head and neck squamous cell carcinoma (HNSCC) remains dismal with 5-year survival less than 40%. This grim prognosis is in distinct contrast to the more than 80% chance of cure for those patients who present with early stage cancer. Unfortunately, more than two-third of patients with HNSCC are diagnosed only after the disease is advanced. Failure to diagnose this cancer early is mainly attributed to the unavailability of a screening test for high risk patients as well as frequent misdiagnosis of early stage cancer by primary physicians. An autoantibody immunoassay for head and neck squamous cell carcinoma (HNSCC) is expected to become a novel non-invasive tool for early diagnosis. Our long term strategy, which would become the subject of a Phase II SBIR grant application should Phase I work be successful, is to develop a "tobacco user's chip" to screen for both HNSCC and lung cancer in one blood sample, because current and former smokers are at high risk for both diseases. The serological test should have a significant impact on the quality of medical care for persons at risk, particularly for over 20% of the US population who are users of tobacco and/or alcohol products. PUBLIC HEALTH RELEVANCE: A blood test for early detection of head and neck cancer could provide a cost-effective screening approach when applied to presently known high risk groups, who are: users of tobacco and/or alcohol, the immune-compromised, and those with premalignant lesions. It would enable a viable strategy for reducing the severe mortality rate of this disease.

描述（由申请人提供）：20/20 GeneSystems，Inc.正在寻求SBIR资助支持。(20/20），一家小型生物技术公司，帮助我们推进我们相信将成为第一个常规使用的血液测试，以帮助早期发现头颈癌。尽管最近在诊断和治疗方式方面取得了进展，但晚期头颈部鳞状细胞癌（HNSCC）患者的长期预后仍然令人沮丧，5年生存率低于40%。这种严峻的预后与那些患有早期癌症的患者超过80%的治愈机会形成鲜明对比。不幸的是，超过三分之二的HNSCC患者只有在疾病进展后才被诊断出来。未能及早诊断这种癌症主要是由于没有为高危患者提供筛查测试，以及初级医生经常误诊早期癌症。头颈部鳞状细胞癌（HNSCC）的自身抗体免疫检测有望成为一种新的非侵入性早期诊断工具。我们的长远策略是发展一种“烟草使用者芯片”，在一个血液样本中同时检测HNSCC和肺癌，因为现在和以前的吸烟者患这两种疾病的风险都很高。血清学检测应该对高危人群的医疗质量产生重大影响，特别是对于超过20%的美国人口，他们是烟草和/或酒精产品的用户。公共卫生关系：血液检测的早期发现的头部和颈部癌症可以提供一个具有成本效益的筛查方法时，适用于目前已知的高风险群体，谁是：烟草和/或酒精的用户，免疫功能低下，和那些与癌前病变。它将为降低这种疾病的严重死亡率提供可行的策略。